About the Study

For adults with a diagnosis of Major Depressive Disorder (MDD) currently experiencing a Major Depressive Episode (MDE).

The goal of this study is to evaluate the efficacy, safety, and tolerability of CYB003 15 mg, compared to placebo, in treating symptoms of MDD in adult participants.
This study is sponsored by Cybin.

Length of Study:  Approximately 4 to 5 months. Qualified participants may be eligible for a long-term extension study.

Eligibility 

You may be eligible to participate in this study if you:

• are between the ages of 18-85 years old
• meet DSM-5 criteria for Major Depressive Disorder (MDD) diagnosis
• are currently on a stable dose of anti-depressant medication for at least 4 weeks, with inadequate response
• are able to remain in our private suite for the entire dosing session (up to 8 hours) for each dosing day

 

If chosen for this study, you will be compensated for every study visit that you complete, and we can provide transportation if needed. 

If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.